Adults suffering from acute ischemic stroke are advised to consider tenecteplase as a therapy option by the National Institute for Health and Care Excellence (NICE). This choice represents a major advancement in the treatment of strokes and may have a big effect on patient care and NHS budget. Boehringer Ingelheim’s Tenecteplase, also marketed under the...
